Description of Velasof
Velasof is a combination medicine, contains an active ingredients like Sofosbuvir and Velpatasvir, both having anti-viral properties.
Velasof is active against virus which is responsible for chronic hepatitis C viral infection.
Velasof is a prescription medicine; it is used by the patient under the supervision of medical practitioner.
Sofosbuvir: HCV NS5B polymerase inhibitor
Velpatasvir: HCV NS5A inhibitor
Trade name: Velasof
Active ingredients: Sofosbuvir and Velpatasvir
Strength of the drug: 400mg and 100mg respectively
Package: 28 tablets in a container
Tablet Velasof Benefits
About 99% curable rates
Cost effective to the patient
Short course (one tablet per day)
Pharmacology of Velasof
Velasof Mechanism of action:
Velasof containing two ingredients which exhibits antiviral activity,
Sofosbuvir: a nonstructural protein 5B polymerase inhibitor, essential for viral multiplication.
Sofosbuvir is a prodrug (nucleotide analog), metabolized into active form called uridine analogue triphosphate (GS-461203)
The metabolite GS-461203 is integrated into hepatitis C virus RNA by NS5B polymerase and performed as a chain terminator.
Velpatasvir: NS5A protein is responsible for RNA replication and aggregation of HCV virions.
Velpatasvir is a NS5A inhibitor which interfere with the enzyme activity and eradicates the viral multiply.
Pharmacokinetics of Velasof tablet:
After oral administration of Velasof tablet, absorption occurs very quickly.
The peak plasma concentration of the Sofosbuvir, Velpatasvir and GS-461203 (active metabolite) occurs within 1 hour, 3 hours and 3 hours respectively.
Effect of food:
The response rate of both Sofosbuvir and Velpatasvir are similar to each other while taking with or without food.
Sofosbuvir is bound to human plasma protein in the range of 61-65%
Velpatasvir is highly bound to plasma protein around >99.5%
The active metabolite GS-461203 has poor protein binding property
Sofosbuvir is largely metabolized in liver, converted to active analogue triphosphate GS-461203
Velpatasvir is eliminated greatly in unchanged form
80%, 14%, and 2.5% of the drug is eliminated through urine, faeces and exhaled air respectively.
The terminal half life of Tablet Velasof is 15 hours.
Indication of Velasof
Velasof is primarily indicated for the patients who are suffered with chronic hepatitis C viral infection associated genotype I, II, III, IV, V or VI infection
There are two conditions like;
Without cirrhosis or with compensated cirrhosis
With decompensated cirrhosis with use of ribavirin
Dose & Dosage's of Velasof
Velasof Dosage and administration:
Velasof is mainly recommended for adults, safety and efficacy of the drug has not been established for children.
Chronic hepatitis C virus (HCV) infection genotypes I, II, III, IV, V or VI
One tablet to be taken as a single dose
Velasof should be taken with or without food
If patient without cirrhosis or compensated cirrhosis (child Pugh A) should take Velasof for 12 weeks
If patient with decompensated cirrhosis (child Pugh B or C) should take Velasof with ribavirin for 12 weeks
The dose of ribavirin recommended on the basis of weight of patient;
<75 kg: 1000mg/day twice daily
≥75 kg: 1200mg/day twice daily
The dosage of ribavirin should be decreased on the basis of hemoglobin and creatine clearance levels.
If patient missed the dose of Velasof tablet, should be skipped and follow the next dose schedule
Do not take double dose
Side Effects of Velasof
Velasof Side effects:
Headache, fatigue, shortness of breath, chest pain
With decompensated cirrhosis
Fatigue, anemia, decreased hemoglobulin levels, nausea, headache, insomnia
1-10% of patients attain;
Lipase increase, rash, depression, increased creatine kinase, insomnia, asthenia
With decompensated cirrhosis;
Diarrhea, hemoglobin levels get depleted, rash, increased creatine kinase
Contraindication of Velasof
Velasof is contraindicated to the pregnant women or become pregnant and children
While taking Velasof with ribavirin causes some defects to the unborn babies
Drug Interaction of Velasof
Velasof Indication: Velasof is primarily indicated for the patients who are suffered with chronic hepatitis C viral infection associated genotype I, II, III, IV, V or VI infection There are two conditions like; Without cirrhosis or with compensated cirrhosis With decompensated cirrhosis with use of ribavirin
Precaution of Velasof
Care should be taking while using Velasof with ribavirin, amiodarone causes;
Serious effects to unborn baby
Patient with liver and kidney disorders
Usage & Safety profile of Velasof Pregnancy & Lactation
Pregnancy and lactation: Generally, Velasof is not prescribed for pregnant women and who become pregnant and children Velasof with ribavirin is contraindicated to pregnant women it may cause fetal death In lactation, some metabolites are excreted in human milk it also cause some ill effects
Storage of Velasof
Velasof should be stored at room temperature.
Velasof container should be keep away from moisture, heat, and light